摘要
支气管哮喘(简称哮喘)是由多种细胞和细胞因子参与的慢性呼吸道炎症性疾病,发病机制可能与Th1/Th2细胞因子失衡、CD4+CD25+ T细胞(调节性T细胞,简称Tregs)及Th17/IL-17等异常有关。白介素35是一种新发现的细胞因子,其与Tregs及Th17/IL-17等免疫调节功能密切相关,通过多种途径参与哮喘的发病和调节,有望成为哮喘的治疗新靶点。本文对此相关研究作一综述。
Bronchial asthma （asthma） is a chronic inflammatory airway disease involved in many cytokines, the mechanism may be related with the imbalance of Th1/Th2 cells or the abnormalities of CD4＋CD25＋T cells, Th17/IL-17 and so on. Interleukin-35 （IL-35） is a newly discovered cytokine, which is closely related to the immune function of Th17/IL-17 and Tregs. IL-35 may be involved in the pathogenesis of asthma, which is expected to become a new target for the treatment of asthma. This review describes the relative researches on IL-35.
出处
《中华哮喘杂志（电子版）》
CAS
2012年第4期42-45,共4页
Chinese Journal of Asthma(Electronic Version)
基金
上海市科学技术委员会资助项目(114119a3200)
关键词
白介素35
哮喘
发病机制
治疗
Interleukin-35
Asthma
Pathogenesis
Treatment
